Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females of infertile couples for whom COS and IVF or ICSI is indicated~* body mass index between 18 and 29 kg/m2~* willing and able to give written informed consent.~Exclusion Criteria:~* More than three previous COS cycles for assisted reproduction since last established ongoing pregnancy (if applicable)~* History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment~* Less than 2 ovaries or any other ovarian abnormality including endometrioma~* Presence of unilateral or bilateral hydrosalpinx~* Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of at least one ovary~* History of or current polycystic ovary syndrome (PCOS)~* History of/or current endocrine abnormality~* Any clinically relevant hormone value outside the reference range during the early follicular phase~* Any clinically significant abnormal laboratory value~* Hypertension or currently treated hypertension~* Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary disease~* Alcohol or drug abuse, or history thereof~* Current serious allergic symptoms~* Abnormal cervical smear~* Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs;~* Contra-indications for the use of gonadotropins~* Use of hormonal preparations within 1 month prior to the date of signing consent;~* Administration of any investigational product within 3 months prior to screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ganirelix
- 2 (Type: ACTIVE_COMPARATOR): triptorelin

Based on this trial design, predict the completion outcome and termination type (if applicable).